Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease
Pharmacy Times
JULY 9, 2025
While no new adverse reactions were observed in this study, higher rates of hypersensitivity and infusion-related reactions were observed. Mayo Clinic. Pharmacy Times. FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease.
Let's personalize your content